Zombie Biotech Bite Lilly’s Flab Fight Flops
This week’s ‘The Readout LOUD’ brings us the sad, slow death of a zombie biotech, proving you can’t just stitch dead companies back to life. Meanwhile, Lilly’s obesity drug results are as underwhelming as a flat soda—described simply as ‘disappointing obesity readout.’ If we were looking for a plot twist, we’d better sit down: pharma’s horror story continues with a whimper rather than a bang.
Share the Story
(1 of 3)When zombie biotechs stumble and Lilly’s obesity hopes deflate, it’s official: pharma’s more horror story than thriller right now.
Nothing like a biotech graveyard plus disappointment in obesity trials to remind us life and science both love an ironic twist.
If your biotech’s a zombie and your obesity study flops, congrats—you’re the pharmaceutical equivalent of a microwave dinner no one really wanted.
Source: Statnews | Published: 8/7/2025 | Author: Adam Feuerstein, Elaine Chen, and Allison DeAngelis
More Articles in Health
Sydney Sweeney's $1M Flop, Trump-Approved Jeans & Bathwater Soap Fiasco
Digital Nomad Trapped in Lisbon FOMO, Ends Up BFF Ghosted
Top Democrats and Trump Son-in-Law Meet Secretly, Assume Peace Talks or Reality TV Reunion
90-Year-Old Dad Outsources Bathing to Jovial Nigerian and Ghanaian Carers
Woman Ages Backwards in Online Writing Class, Still Loses to 21-Year-Old
Billionaire’s Daughter’s Brain Hemorrhage Detected Belatedly By $299 Ring
Dietitians Unite to Demand We Eat More Beans, Save Humanity from Boredom
Mark Cuban Declares AI Too Empathetic to Replace Doctors, Only Bullshit Jobs Fear
